AFFILIN
LIVE

Serial Number

79155885

Owner

Scil Proteins GmbH

Attorney

Miki Motohashi Iino

Filing Date

Jul 29, 2014

Add to watchlist:

No watchlists yet
View on USPTO

AFFILIN Trademark

Serial Number: 79155885 • Registration: 4838850

AFFILIN is a trademark filed by Scil Proteins GmbH on July 29, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Scil Proteins GmbH (3 trademarks)

Heinrich-Damerow-Str. 1

Entity Type: 99

Trademark Details

Filing Date

July 29, 2014

Registration Date

October 27, 2015

Published for Opposition

August 11, 2015

Goods & Services

[Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]

[Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]

Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Feb 2, 2026 NA71
REGISTERED-SEC.71 ACCEPTED
Feb 2, 2026 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 26, 2026 APRE
TEAS SECTION 71 RECEIVED
Sep 14, 2025 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Oct 28, 2024 REM4
INTERNATIONAL REGISTRATION RENEWED
May 24, 2024 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Apr 30, 2023 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 9, 2023 INPS
INVALIDATION PROCESSED
Mar 9, 2023 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 17, 2023 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
May 17, 2022 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
May 17, 2022 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 10, 2022 APRE
TEAS SECTION 71 RECEIVED
Oct 26, 2021 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 27, 2020 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 15, 2016 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 12, 2016 FICS
FINAL DISPOSITION PROCESSED
May 12, 2016 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 27, 2016 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 27, 2015 R.PR
NOTIFICATION PROCESSED BY IB
Aug 21, 2015 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 11, 2015 NPUB
PUBLISHED FOR OPPOSITION
Aug 11, 2015 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 5, 2015 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 5, 2015 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 22, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 8, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 7, 2015 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 6, 2015 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 6, 2015 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 6, 2015 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 6, 2015 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2015 CRFA
ASSIGNED TO LIE
Jun 17, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 10, 2015 TROA
REFUSAL PROCESSED BY IB
Dec 27, 2014 RFNT
APPLICATION FILING RECEIPT MAILED
Dec 12, 2014 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 10, 2014 RFCS
REFUSAL PROCESSED BY MPU
Dec 10, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 9, 2014 RFCR
NON-FINAL ACTION WRITTEN
Dec 8, 2014 CNRT
ASSIGNED TO EXAMINER
Dec 8, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 8, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 4, 2014 REPR